TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01711294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19 G Flex Needle
Description: Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
Study: NCT03629080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-101 vaccine
Description: HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-101 vaccine
Description: HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline will be used for placebo.
Study: NCT01711294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 G Needle
Description: Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19 G Needle
Description: Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
Study: NCT03629080

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline will be used for placebo.
Study: NCT02938377

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Brief Intervention (CBI)
Description: A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Brief Intervention (CBI)
Description: A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Brief Intervention (CBI)
Description: A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT4CBT
Description: 9 computerized modules delivered at the participant's pace
Study: NCT03999788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar puncture and blood withdrawal
Description: lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar puncture and blood withdrawal
Description: lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity
Description: iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
Study: NCT05825274

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cathodal tDCS
Description: We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
Study: NCT02938377

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT4CBT
Description: 9 computerized modules delivered at the participant's pace

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recommendation and Counseling for Alcohol Pharmacotherapy
Description: The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
Study: NCT05825274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Description: We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
Study: NCT02399319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Fixator
Description: Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
Study: NCT02206867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBAL
Description: Anti-inflammatory agents

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Description: Anti-inflammatory agents
Study: NCT02399319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Fixator
Description: Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Symphyseal Plate
Description: A plate that spans across the symphysis to maintain reduction and stability.
Study: NCT00252499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: PPAR-alpha agonist, reduces triglycerides
Study: NCT01480375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartbx™ system.
Description: The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
Study: NCT04131257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Continuum of Care
Description: This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led Continuum of Care
Description: This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
Study: NCT03041090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lucerno ID (identification) System
Description: The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lucerno ID (identification) System
Description: The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
Study: NCT03053414

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (ergocalciferol and/ or cholecalciferol)
Description: To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (ergocalciferol and/ or cholecalciferol)
Description: To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (ergocalciferol and/ or cholecalciferol)
Description: To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
Study: NCT00252499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for rosiglitazone
Description: placebo tablets that are matched to look like rosiglitazone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for rosiglitazone
Description: placebo tablets that are matched to look like rosiglitazone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for fenofibrate
Description: placebo matched to look like fenofibrate tablets
Study: NCT01673399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00853528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
Study: NCT00252499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for fenofibrate
Description: placebo matched to look like fenofibrate tablets
Study: NCT00383643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zolpidem tartrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium oxybate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebos

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebos

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebos
Study: NCT04410666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Tea mouthwash
Description: an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C, in sterile glass containers.~Each application was 10 ml. applied for 1 minute.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouthwash
Description: distilled water
Study: NCT01556048

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Activation
Description: Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
Study: NCT03894969

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E
Description: 2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E
Description: 2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E
Description: 2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
Study: NCT04615728

Intervention type: PROCEDURE
Intervention: laparoscopic or open appendicectomy
Description: Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection

Intervention type: PROCEDURE
Intervention: laparoscopic or open appendicectomy
Description: Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
Study: NCT02255240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
Study: NCT03010059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral suspension formulation)
Description: Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral suspension formulation)
Description: Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
Study: NCT03894969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E
Description: 2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
Study: NCT03053414

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (ergocalciferol and/ or cholecalciferol)
Description: To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
Study: NCT01453114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
Study: NCT03676933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107E

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: Steroid taken topically once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: Steroid taken topically once a day
Study: NCT01905384

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered Self-expanding metal biliary stents (C-SEMS)
Description: Used for palliation of inoperable malignant distal bile duct obstruction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered Self-expanding metal biliary stents (U-SEMS)
Description: Used for palliation of inoperable malignant distal bile duct obstructions.
Study: NCT00775151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 10 mg tablet
Study: NCT03804944

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Focal Radiation therapy
Description: Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Focal Radiation therapy
Description: Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Focal Radiation therapy
Description: Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Focal Radiation therapy
Description: Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab (200mg IV for 30 minutes
Description: Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab (200mg IV for 30 minutes
Description: Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CDX-301
Description: Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CDX-301
Description: Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
Study: NCT03579589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex vs Neostigmine
Description: Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.
Study: NCT03894969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
Description: 2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
Description: 2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
Description: 2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
Description: 2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
Study: NCT02477254

Intervention type: BIOLOGICAL
Intervention: Vaccination
Description: A quadrivalent HPV vaccine
Study: NCT00853528

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: single-fraction SRS
Description: two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: single-fraction SRS
Description: two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
Study: NCT03862469

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Individualized laboratory test
Description: Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.
Study: NCT03028480

Intervention type: DRUG
Intervention: NUCALA Injection
Description: Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
Study: NCT02536300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally